These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26667449)

  • 1. Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
    López AM; Pruthi S; Boughey JC; Perloff M; Hsu CH; Lang JE; Ley M; Frank D; Taverna JA; Chow HH
    Cancer Prev Res (Phila); 2016 Feb; 9(2):142-8. PubMed ID: 26667449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
    Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
    Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
    Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
    Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
    Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
    Dixon JM; Renshaw L; Dixon J; Thomas J
    Breast Cancer Res Treat; 2011 Dec; 130(3):871-7. PubMed ID: 21870129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
    Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
    Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
    Scott LJ; Keam SJ
    Drugs; 2006; 66(3):353-62. PubMed ID: 16526826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
    Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
    Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
    Tan WW; Allred JB; Moreno-Aspitia A; Northfelt DW; Ingle JN; Goetz MP; Perez EA
    Clin Breast Cancer; 2016 Apr; 16(2):82-6. PubMed ID: 26774555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
    Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
    J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.